Subscribe to HARMONY newsletter
 

Blood cancers, or haematologic cancers (e.g. leukaemia, lymphoma and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use ‘big data and big data analytics’ to deliver information that will help to improve the care of patients with these diseases. Specifically, this IMI project will gather together, integrate and analyse patient data from a number of high quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognised by all key stakeholders of the Healthcare system. Meanwhile the project’s generated insights will facilitate and improve decision making along the value chain to ultimately give the right treatment to the right patient at the right time. More broadly, the project will result in a pan-European network of stakeholders with expertise in this disease area.

https://www.harmony-alliance.eu/

Partners

  •        Agencia Española de Medicamentos y Productos Sanitarios
  •        Alma Mater Studiorum – Università di Bologna
  •        Amgen
  •        Assistance Publique – Hôpitaux de Paris
  •        Barts Health NHS Trust
  •        BAYER
  •        Bundesinstitut für Arzneimittel und Medizinprodukte
  •        CELGENE
  •        ELN Foundation
  •        Erasmus Universiteit Medisch Centrum Rotterdam
  •        European Alliance for Personalised Medicine
  •        European Hematology Association
  •        European Organisation for Research and Treatment of Cancer
  •        European Research Initiative on CLL e.v.
  •        European Society for Blood and Marrow Transplantation
  •        Flanders Institute of Biotechnology
  •        Fondazione Italiana per lo studio delle sindromi mielodisplastiche onlus
  •        Fundacio privada Institut D’investigacio Oncologica de Vall-Hebron
  •        Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
  •        Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana
  •        Genome Research Limited
  •        German Society of Pediatric Oncology-Hematology GmbH gemeinnützig
  •        GMV Soluciones Globales Internet S.A.U.
  •        Goethe University Frankfurt
  •        Group for Research on Adult Acute Lymphoblastic Leukemia
  •        Groupe Francophone des Myélodysplasies
  •        Heinrich-Heine-Universitaet – Duesseldorf
  •        Jose Carreras Leukaemia Research Institute
  •        JPNV-JANSSEN
  •        LeukaNET
  •        Ludwig-Maximilians-Universitaet – Muenchen
  •        Masaryk University
  •        MediSapiens Ltd
  •        Medizinische Universitaet – Wien
  •        MENARINI
  •        MLL Munich Leukemia Laboratory GmbH
  •        National Institute for Health and Care Excellence
  •        NOVARTIS
  •        Ospedale Pediatrico Bambino Gesù
  •        Synapse Research Management Partners
  •        TAKEDA
  •        The Chancellor, Masters and Scholars of the University of Cambridge
  •        The Lymphoma Scientific Association
  •        Università degli Studi di Torino
  •        Universitaet Ulm
  •        University of Helsinki
  •        University of Navarra
  •        University of Newcastle upon Tyne
  •        University of Rome ‘Tor Vergata’
  •        University of York)
  •        VU University Medical Center